Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

1589 results found

2023 ∙ Kandeel, M. Morsy, M. A. Abd El-Lateef, H. M. Marzok, M. El-Beltagi, H. S. Al Khodair, K. M. Albokhadaim, I. Venugopala, K. N.

Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines

  • Adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Stefanou, M. I. Palaiodimou, L. Theodorou, A. Christodoulou, M. V. Tzartos, J. S. Tzanetakos, D. Kitsos, D. Chondrogianni, M. Zouvelou, V. Dardiotis, E. Tzavellas, E. Syrigou, E. Benetou, V. Paraskevas, G. P. Tsiodras, S. Tsivgoulis, G. Giannopoulos, S.

Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Moderate
2023 ∙ van de Pol, N. Pan, Q. Derikx, Laap Bakker, L. van der Woude, C. J. de Vries, A. C.

SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Liang, Y. Sun, Q. Liu, Q. Pang, Y. Tang, S.

SARS-CoV-2 incidence, seroprevalence, and COVID-19 vaccination coverage in the homeless population: a systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2023 ∙ Jing, X. Han, M. Wang, X. Zhou, L.

SARS-CoV-2 vaccine breakthrough infection in the older adults: a meta-analysis and systematic review

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Søndergaard, M. H. Thavarajah, J. J. Churchill Henson, H. Wejse, C. M.

SARS-CoV-2 vaccine immunogenicity for people living with HIV: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Y. Elzouki, A. N. Elshafei, M. N. Aziz, A. Elzouki, I. Waheed, M. A. Farooqui, K. Azad, A. M. Habas, E. Danjuma, M. I.

Seroconversion and safety of Covid-19 vaccines in patients with chronic liver disease and liver transplant: A systematic review

  • Adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Gkoufa, A. Lekakis, V. Papatheodoridis, G. Cholongitas, E.

Seroconversion following a booster dose of COVID-19 vaccine in liver transplant recipients. A systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Iryaningrum, M. R. Cahyadi, A. Damara, F. A. Bandiara, R. Marbun, M. B. H.

Seroconversion rates in kidney transplant recipients following SARS-CoV-2 vaccination and its association with immunosuppressive agents: a systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2023 ∙ Wang, Y. Chen, D. Pan, Y. Li, H. Zhao, W. Lu, T. Kong, W. Ding, M. Wang, X. Zhang, G.

Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
Loading...